In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: A PET and MRI study
Open accessAbstract
Background Microglial activation and disrupted neurotransmissions may herald symptomatic manifestations in neurodegenerative tauopathies.Methods We investigated microglial activation with [(11)C]DAA1106 positron emission tomography (PET), striatal dopaminergic function with l-[beta-(11)C]dopa PET, acetylcholinesterase (AChE) activity with [(11)C]N-methylpiperidin-4-yl acetate PET, and morphologic brain changes with MRI in three persons (aged 38-41 years) with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), who were presymptomatic gene carriers (PGCs) from an American kindred with pallidopontonigral degeneration. The results from these 3 PGCs were compared with [(11)C]DAA1106 PET results from age-matched 9 healthy volunteers (HV), and with l-[beta-(11)C]dopa and [(11)C]MP4A PET results from 10 HV. Values considered significant were more than 2 SDs greater or less than the normal control mean, as the number of subjects was small for group comparisons.Results Glial activities were increased in the frontal cortex of one PGC, the occipital cortex of two PGCs, and the posterior cingulate cortex of one PGC, although none of the PGCs showed overt glial activation in the brain. Only one of the PGCs showed reduced AChE activity in the temporo-parietal cortex. Three PGCs showed low dopamine synthesis rates in the putamen. Hippocampal atrophy was observed in two PGCs.Conclusions Hippocampal atrophy and striatal dopaminergic dysfunction may be early disease processes in the pathogenesis of FTDP-17. Neuroinflammation may also be an in vivo signature of tau pathology at a prodromal stage, although current PET techniques may not constantly reveal it as the earliest neuroimaging abnormality.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TPSO signal increases with microglia activation in tauopathies including AD, PSP, PiD, and FTDP-17.
“TPSO signal has been shown to increase with microglia activation in tauopathies including AD, PSP, PiD, and FTDP-17 [111–113] as well as several other neurodegenerative diseases and injury models such as other frontotemporal dementias (FTDs), Parkinson’s disease, stroke and TBI [114].”
From Glial contributions to neurodegeneration in tauopathies (2017) · cites this paper as [112]
Cites
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965 · see citing works
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208 · see citing works
Self-citationIn vivo detection of microglial activation in frontotemporal dementia
Cagnin, A., Rossor, M., Sampson, E. L., MacKinnon, T., & Banati, R. B. (2004) · Annals of Neurology · doi:10.1002/ana.20332 · Cited by 187 · cited 1× · see citing works
“A PBR ligand, [11C](R)-PK11195, has been widely used for PET analyses as a marker of activated microglia in brain diseases including frontotemporal dementia and presymptomatic Huntington’s disease gene carriers [8,23,24].”
MethodJi, B., Maeda, J., Sawada, M., Ono, M., Okauchi, T., Inaji, M., Zhang, M.-R., Suzuki, K., Ando, K., Staufenbiel, M., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2312-08.2008 · Cited by 169 · see citing works
Self-citationPositron Emission Tomography Imaging of Neuroinflammation
Cagnin, A., Kassiou, M., Meikle, S. R., & Banati, R. B. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.04.006 · Cited by 137 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Rohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538 · see citing works
Glial contributions to neurodegeneration in tauopathies
Leyns, C. E. G., & Holtzman, D. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0192-x · Cited by 409 · see citing works
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics
Whitwell, J. L., Weigand, S. D., Boeve, B. F., Senjem, M. L., Gunter, J. L., DeJesus-Hernandez, M., Rutherford, N. J., Baker, M., Knopman, D. S., Wszolek, Z. K., et al. (2012) · Brain · doi:10.1093/brain/aws001 · Cited by 397 · see citing works
Self-citationDupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182 · see citing works
Maeda, J., Zhang, M.-R., Okauchi, T., Ji, B., Ono, M., Hattori, S., Kumata, K., Iwata, N., Saido, T. C., Trojanowski, J. Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3076-10.2011 · Cited by 136 · see citing works
Self-citationNeuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Kaalund, S. S., Passamonti, L., Allinson, K., Green, O., Hong, Y. T., Fryer, T. D., Arnold, R., et al. (2020) · Brain · doi:10.1093/brain/awaa033 · Cited by 124 · see citing works
Neuroinflammation predicts disease progression in progressive supranuclear palsy
Malpetti, M., Passamonti, L., Jones, P. S., Street, D., Rittman, T., Fryer, T. D., Hong, Y. T., Vàsquez Rodriguez, P., Bevan-Jones, W. R., Aigbirhio, F. I., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325549 · Cited by 85 · see citing works
Cerami, C., Iaccarino, L., & Perani, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050993 · Cited by 75 · see citing works
Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging
Zhang, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0236-5 · Cited by 62 · see citing works
In vivo PET imaging of neuroinflammation in familial frontotemporal dementia
Malpetti, M., Rittman, T., Jones, P. S., Cope, T. E., Passamonti, L., Bevan-Jones, W. R., Patterson, K., Fryer, T. D., Hong, Y. T., Aigbirhio, F. I., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323698 · Cited by 43 · see citing works
In vivo evidence for pre‐symptomatic neuroinflammation in a <scp>MAPT</scp> mutation carrier
Bevan‐Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J. P., Aigbirhio, F. I., O'Brien, J. T., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.683 · Cited by 36 · see citing works
Cheran, G., Wu, L., Lee, S., Manoochehri, M., Cines, S., Fallon, E., Lynch, T., Heidebrink, J., Paulson, H., Goldman, J., et al. (2019) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617718001005 · Cited by 29 · see citing works
Ikeda, A., Shimada, H., Nishioka, K., Takanashi, M., Hayashida, A., Li, Y., Yoshino, H., Funayama, M., Ueno, Y., Hatano, T., et al. (2019) · Movement Disorders · doi:10.1002/mds.27623 · Cited by 22 · see citing works
Self-citation
- Authors
- Miyoshi, M., Shinotoh, H., Wszolek, Z. K., Strongosky, A. J., Shimada, H., Arakawa, R., Higuchi, M., Ikoma, Y., Yasuno, F., Fukushi, K., Irie, T., Ito, H., & Suhara, T.
- Affiliations
- National Institute of Radiological Sciences (JP)
- Mayo Clinic in Florida (US)
- ORCID
- Venue
- Parkinsonism & Related Disorders
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 16
- Issue
- 6
- Pages
- 404-408
- ISSN
- 1353-8020 (ISSN-L)
- OpenAlex
- W2003056501
- Cited by
- 75
- References
- 5
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 7 · 2020: 15 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 1 · 2015: 5 · 2014: 3 · 2013: 3 · 2012: 4
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- green
- repo.qst.go.jp
- Licence
- Locations
- Parkinsonism & Related Disorders (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institute on Aging (R01AG015866, P01AG017216)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- MAPT mutations
- MeSH terms
- Adult, Brain, Heterozygote, Humans, Image Interpretation, Computer-Assisted, Magnetic Resonance Imaging, Mutation, Neuropsychological Tests, tau Proteins, Positron-Emission Tomography, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
